Gilead Sciences (GILD) Shareholder's Equity Growth (5y) (2014 - 2026)

Gilead Sciences (GILD) Shareholder's Equity Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 4.40%
Dec 31, 2025 4.50%
Sep 30, 2025 4.28%
Jun 30, 2025 1.55%
Mar 31, 2025 -2.97%
Dec 31, 2024 -3.20%
Sep 30, 2024 -2.37%
Jun 30, 2024 -4.37%
Mar 31, 2024 -4.60%
Dec 31, 2023 1.10%
Sep 30, 2023 -0.67%
Jun 30, 2023 -0.60%
Mar 31, 2023 0.28%
Dec 31, 2022 0.68%
Sep 30, 2022 -3.25%
Jun 30, 2022 -2.63%
Mar 31, 2022 -0.52%
Dec 31, 2021 1.70%
Sep 30, 2021 4.94%
Jun 30, 2021 4.11%